How WCG accelerates study cycles to provide your competitive advantage
Every clinical study sponsor strives to achieve the shortest possible study cycle. Yet fully 80% of trials fall behind. The reason for delays and missed deadlines is rarely a single problem.
Study launches are nearly always inhibited by a constellation of variables: Sluggish IRB reviews, fraught contract negotiations, poor-performing sites, too few recruitment staff, too small a patient pool, inadequate enrollment skills, or insensitive informed consent.
To address the variety of obstacles that may inhibit your clinical trial, our Fast Start Solution identifies the key causes—or potential causes—likely to slow your study launch. We then recommend specific acceleration services to overcome each of your obstacles and put the study on a fast track.
If your trial is running behind—or you want to leap-frog delays for your next study—let us analyze your study and offer services that can reduce average launch times by 33% across all therapeutic indications.